Please assess the completion status of the following clinical trial:

Trial Title: Safety, Efficacy, and Treatment Satisfaction Switching From Flolan to Remodulin Using the Crono Five Ambulatory Pump in Patients With PAH

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Age 18 to 65 years~* Diagnosis of one of the following WHO Classifications of pulmonary hypertension:~  1. Group 1 pulmonary arterial hypertension~     * Idiopathic pulmonary arterial hypertension (IPAH)~    * Familial pulmonary arterial hypertension (FPAH)~    * Associated pulmonary arterial hypertension (APAH):~       1. collagen vascular disease~      2. congenital systemic-to-pulmonary shunt repaired greater than 5 years prior to study entry.~      3. portal hypertension~      4. drugs and toxins~ 2. Group 4 pulmonary hypertension due to chronic thromboembolic pulmonary hypertension (CTEPH)~* WHO Class II-III~* Currently receiving intravenous epoprostenol therapy for at least three months and a stable dose for at least one month.~* Have central intravenous catheter~* Optimally treated with conventional pulmonary hypertension therapy and clinically stable for at least one month.~* Mentally and physically capable of learning to administer Remodulin using an intravenous infusion pump.~Exclusion Criteria:~* nursing or pregnant woman~* received a new type of chronic therapy (including but not limited to oxygen, a different category of vasodilator, a diuretic, digoxin, bosentan, sildenafil) for pulmonary hypertension added within the last month.~* Had any PAH medication discontinued within the week prior to study entry.~* Received any prostacyclin or prostacyclin analog except epoprostenol in the past 3 months.~* Had a central venous line infection within the past 30 days.~* Previous documented evidence of significant parenchymal lung disease as evidenced by pulmonary function tests as follows (any one of the following):~  1. Total Lung Capacity ≤ 60% (predicted) or~ 2. If Total Lung Capacity is between 60% and 70% (predicted), a High Resolution Computed Tomography (CT) scan must be performed to rule out diffuse interstitial fibrosis or alveolitis~* History of or evidence of left-sided heart disease~* Having any other disease that is associated with pulmonary hypertension (e.g. sickle cell anemia, schistosomiasis).~* Having a musculoskeletal disorder (e.g. arthritis, artificial leg, etc.) or any other disease, which is thought to limit ambulation, or be connected to a machine, which is not portable.~* Uncontrolled systemic hypertension as evidenced by a systolic blood pressure greater than 160 millimeters of mercury (mmHg) or diastolic blood pressure greater than 100 mmHg.~* Chronic renal insufficiency as defined by serum creatinine greater than 2.5 milligrams per deciliter (mg/dL) or the requirement for dialysis.~* Receiving an investigational drug, have in place an investigational device, or have participated in an investigational drug study within the past 30 days.~* Active infection, or any other ongoing condition that would interfere with the interpretation of study assessments.~* The presence of any physiological or psychological condition that contraindicates the administration of Remodulin.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 65 Years
- Healthy Volunteers: f

Study Arms:
- treprostinil (Type: EXPERIMENTAL): IV treprostinil continuous infusion via Crono Five infusion pump.

Based on this trial design, predict the completion outcome and termination type (if applicable).